Compare LCTX & WILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | WILC |
|---|---|---|
| Founded | 1990 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Food Distributors |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 351.4M |
| IPO Year | 1996 | 2001 |
| Metric | LCTX | WILC |
|---|---|---|
| Price | $1.51 | $26.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 1.8K |
| Earning Date | 03-05-2026 | 03-20-2026 |
| Dividend Yield | N/A | ★ 3.14% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $55.75 | N/A |
| Revenue Next Year | $2.96 | N/A |
| P/E Ratio | ★ N/A | $13.45 |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.37 | $12.54 |
| 52 Week High | $2.09 | $31.16 |
| Indicator | LCTX | WILC |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 46.29 |
| Support Level | $0.94 | $26.16 |
| Resistance Level | $1.84 | $28.66 |
| Average True Range (ATR) | 0.11 | 0.81 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 2.06 | 35.71 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.